Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk - PACE-CME

Unexpectedly large CV benefit with icosapent ethyl in statintreated patients at high CV risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Lowering Lp(a) potently and safely with antisense technology
Lowering Lp(a) potently and safely with antisense technology
AHA 2018
Lowering Lp(a) potently and safely with antisense technology
- Sotirios Tsimikas, MD
Physical activity: every step counts, for everybody
Physical activity: every step counts, for everybody
AHA 2018
Physical activity: every step counts, for everybody
- Admiral Brett Giroir, MD
Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort
Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort
AHA 2018
Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort
- JoAnn Manson, MD
Comprehensive US approach to stimulate physical activity should tackle obesity and improve health
Comprehensive US approach to stimulate physical activity should tackle obesity and improve health
AHA 2018
Comprehensive US approach to stimulate physical activity should tackle obesity and improve health
- Dr. Ivor Benjamin